Pascal Biosciences Announces Year-End Investor Update Webcast
10 Diciembre 2018 - 7:45PM
Advancement of Cannabinoid Cancer Programs and
Corporate Review to be Presented
Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a
drug discovery and development company, announced today it will
host a year-end investor update webcast on Thursday, Dec. 17, 2018
at 1:30 p.m. PST.
Dr. Patrick Gray, CEO of Pascal Biosciences,
will describe recent advances in the Company’s cannabinoid-based
therapeutics for cancer and will also provide a review of key
achievements for the Company in 2018.
The live webcast will take place on Thursday,
December 17, 2018 at 1:30 p.m. PST. The webcast can be accessed
from the news page of the Pascal Biosciences website at:
https://www.pascalbiosciences.com/news/. The webcast will be
archived for 30 days. Investors can direct questions to
invest@pascalbiosciences.com.
Highlights of notable 2018 milestones at Pascal to be discussed
during the webcast include:
- Exclusive licensing of ST-403, a cannabinoid-based product for
the treatment of glioblastoma and brain metastases. Pascal has a
development plan to begin human clinical studies of ST-403 in
2019.
- Identification of potential therapeutics in
cannabis that stimulate the immune system to destroy cancer
cells. Both natural and synthetic cannabinoids have been
extensively studied in multiple immune assays.
- Addition of renowned cannabis researcher Dr. Nephi Stella as
scientific consultant to Pascal. Dr. Stella is founder and
co-director of the University of Washington Center for Cannabis
Research, and has worked on cannabinoids for over 20 years.
- Receipt of Drug Enforcement Administration
(DEA) Schedule I License for cannabinoid development. This
licensing allows Pascal to conduct research and
development on cannabinoids.
- Expansion of leadership team to support program
development.
About Pascal Biosciences Inc.
Pascal Biosciences is a biotechnology company focused on
advancing innovative approaches for the treatment of cancer
including cannabinoid-based therapeutics and targeted therapies.
The company’s leading cannabinoid portfolio comprises a small
molecule therapeutic, ST-403, that is advancing into clinical
trials for the treatment of glioblastoma, and an immuno-stimulatory
molecule. In addition, Pascal Biosciences is developing a B-cell
targeted antibody for acute lymphoblastic leukemia and an antibody
for calcium channels expressed by the immune system. For more
information, visit www.pascalbiosciences.com.
Investors: invest@pascalbiosciences.com Tel:
206-221-3443
Media Contact: Julie Rathbun Tel:
206-769-9219
DISCLAIMER Certain statements in this press
release contain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities
legislation that may not be based on historical fact, including
without limitation statements containing the words “believe”,
“may”, “plan”, “will”, “estimate”, “continue”, “anticipate”,
“intend”, “expect” and similar expressions. Such forward-looking
statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
events or developments, or industry results, to be materially
different from any future results, events or developments express
or implied by such forward-looking statements or information. Such
factors include, among others, our stage of development, lack of
any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining
regulatory approval to market our products, the ability to protect
our intellectual property, dependence on collaborative partners and
the prospects for negotiating additional corporate collaborations
or licensing arrangements and their timing. Specifically, certain
risks and uncertainties that could cause such actual events or
results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results
expressed or implied by such statements and information include,
but are not limited to, the risks and uncertainties that: products
that we develop may not succeed in preclinical or clinical trials,
or future products in our targeted corporate objectives; our future
operating results are uncertain and likely to fluctuate; we may not
be able to raise additional capital; we may not be successful in
establishing additional corporate collaborations or licensing
arrangements; we may not be able to establish marketing and the
costs of launching our products may be greater than anticipated; we
have no experience in commercial manufacturing; we may face unknown
risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and
other factors as described in detail in our filings with the
Canadian securities regulatory authorities at www.sedar.com.
Given these risks and uncertainties, you are cautioned not to place
undue reliance on such forward-looking statements and information,
which are qualified in their entirety by this cautionary statement.
All forward-looking statements and information made herein are
based on our current expectations and we undertake no obligation to
revise or update such forward- looking statements and information
to reflect subsequent events or circumstances, except as required
by law.“Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release”
Pascal Biosciences (TSXV:PAS)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Pascal Biosciences (TSXV:PAS)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024